Literature DB >> 4129196

In vitro immunization to cultured human tumor cells.

B Sharma, P I Terasaki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4129196

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

1.  Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2.

Authors:  T Fukiage; H Murakami; M Eura; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Interleukin-2 activated peripheral blood lymphocytes and the correlation of lytic activity and peanut agglutinin receptor expression on malignant cells.

Authors:  Y I Gotoh; M Minegishi; Y Yamaguchi; T Konno; K Tada
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

3.  Inhibition of the generation of cytotoxic lymphocytes by potassium ion channel blockers.

Authors:  B Sharma
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

4.  Antigen-specific primary cytotoxic T lymphocyte (CTL) responses in acquired immune deficiency syndrome (AIDS) and AIDS-related complexes (ARC).

Authors:  B Sharma; S Gupta
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

5.  Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.

Authors:  A Mazumder; E A Grimm; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Successful immunotherapy of murine melanoma metastases with 7-thia-8-oxoguanosine.

Authors:  B S Sharma; L Balazs; A Jin; W B Jolley; R K Robins
Journal:  Clin Exp Metastasis       Date:  1991 Sep-Oct       Impact factor: 5.150

7.  Measurement of polyene antibiotic-mediated erythrocyte damage by release of hemoglobin and radioactive chromium.

Authors:  E B Siegel
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.